D. Clifford

Publications310
h-index73
Citations21,352
Highly Influential Citations1,205
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • I. Grant
  • 716 Publications, 44,431 Citations
  • R. Ellis
  • 385 Publications, 18,911 Citations
  • J. McArthur
  • 521 Publications, 40,378 Citations
  • S. Letendre
  • 340 Publications, 14,846 Citations
  • Publications
  • Influence
Updated research nosology for HIV-associated neurocognitive disorders
In 1991, the AIDS Task Force of the American Academy of Neurology published nomenclature and research case definitions to guide the diagnosis of neurologic manifestations of HIV-1 infection. Now, 16… Expand
  • 1,928
  • 243
  • PDF
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy
Objectives: This is a cross-sectional, observational study to determine the frequency and associated features of HIV-associated neurocognitive disorders (HAND) in a large, diverse sample of infected… Expand
  • 1,583
  • 107
  • PDF
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors
Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders (HAND) continue to be… Expand
  • 1,104
  • 86
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
OBJECTIVE To evaluate whether penetration of a combination regimen into the central nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is associated with lower… Expand
  • 724
  • 54
  • PDF
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
BACKGROUND Treatment of multiple sclerosis with natalizumab is complicated by rare occurrence of progressive multifocal leukoencephalopathy (PML). Between July, 2006, and November, 2009, there were… Expand
  • 560
  • 37
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
Objectives: Efavirenz is an effective antiretroviral agent, but central nervous system side effects occur commonly, and population (racial) differences in pharmacokinetics and response have been… Expand
  • 629
  • 34
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
BACKGROUND Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had… Expand
  • 770
  • 27
  • PDF
HIV and Aging: State of Knowledge and Areas of Critical Need for Research. A Report to the NIH Office of AIDS Research by the HIV and Aging Working Group
Abstract:HIV risk behaviors, susceptibility to HIV acquisition, progression of disease after infection, and response to antiretroviral therapy all vary by age. In those living with HIV, current… Expand
  • 395
  • 21
  • PDF
Progressive multifocal leukoencephalopathy and other forms of JC virus disease
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by the JC virus (JCV). PML usually occurs via reactivation of JCV when an immune system becomes… Expand
  • 182
  • 20
PML diagnostic criteria
Objective: To establish criteria for the diagnosis of progressive multifocal leukoencephalopathy (PML). Methods: We reviewed available literature to identify various diagnostic criteria employed.… Expand
  • 300
  • 18